La Roche-Posay Mela B3 Serum Dark Spot Corrector — 10% Niacinamide & Melasyl™ for Even, Radiant Skin

La Roche-Posay Mela B3 Serum is a targeted facial serum that reduces the look of persistent dark spots and uneven pigmentation using Melasyl™ and 10% niacinamide.

This lightweight corrective serum combines a newly developed Melasyl multi-patented ingredient with a high concentration of niacinamide (vitamin B3) to visibly lighten sunspots, age spots and post-acne marks while boosting skin radiance. Clinically tested for lasting results, the formula is designed to be gentle—non-comedogenic, paraben-free and allergy-tested—so it can be integrated into both morning and evening skin routines. For daytime use, pairing it with an SPF moisturizer helps maintain results and protect treated areas from new discoloration.

How quickly will I notice a reduction in dark spots?

Individual results vary, but clinical use notes visible improvement within weeks. Many users report measurable reduction in persistent dark spots by about eight weeks when used consistently twice daily.

• Apply 3–4 drops to clean face and neck morning and evening, avoiding the eye area.
• Consistent twice-daily application yields best results over several weeks.
• Daily SPF in the morning prevents new pigmentation and supports long-term outcomes.

What makes Melasyl™ and niacinamide work together?

Melasyl™ is a multi-patented ingredient developed to target the processes that contribute to discoloration, while niacinamide helps fade visible pigmentation and supports a more even tone. Combined, they address both existing dark spots and the overall radiance of skin without being overly aggressive.

• Melasyl™: patented actives designed to reduce persistent discoloration.
• 10% niacinamide: a stable form of vitamin B3 known to improve skin tone appearance.
• Supports skin radiance and a smoother, more uniform complexion.

Is this serum suitable for sensitive or acne-prone skin?

The formula is allergy-tested, non-comedogenic and paraben-free, making it appropriate for many skin types, including those prone to breakouts or sensitivity. As with any active product, introduce it gradually and watch for any irritation.

• Non-comedogenic: designed not to block pores.
• Allergy-tested: intended to minimize irritation risk.
• Pair with gentle cleansers and avoid mixing with other strong exfoliating actives without guidance.

How should I incorporate Mela B3 Serum into my routine?

Use the serum after cleansing and before moisturizing; apply a few drops to face and neck both morning and night. In the morning, follow with a broad-spectrum sunscreen or a dedicated SPF moisturizer to protect results and prevent new spots.

• Step 1: Cleanse and dry skin thoroughly.
• Step 2: Dispense 3–4 drops and smooth over face and neck, avoiding eyes.
• Step 3: Lock in with moisturizer; use SPF in daytime.

Who this is for: La Roche-Posay Mela B3 Serum is aimed at people seeking a targeted, scientifically developed approach to reducing visible dark spots, sun damage and post-acne marks while improving overall skin luminosity. It suits those looking for a dermatologist-backed, non-irritating treatment to add to a daily skincare regimen—particularly anyone wanting to combine a potent pigmentation solution with gentle, everyday use.

Ingredients

INGREDIENTS: AQUA / WATER / EAU • DIMETHICONE • NIACINAMIDE • GLYCERIN • PROPYLENE GLYCOL • POLYSILICONE-11 • SILICA • BIS-PEG/PPG-16/16 PEG/PPG-16/16 DIMETHICONE • CYSTOSEIRA TAMARISCIFOLIA EXTRACT • 2-MERCAPTONICOTINOYL GLYCINE • PEG-20 METHYL GLUCOSE SESQUISTEARATE • SODIUM HYALURONATE • SODIUM HYDROXIDE • SODIUM THIOSULFATE • CARNOSINE • POLOXAMER 338 • AMMONIUM POLYACRYLOYLDIMETHYL TAURATE • DIPOTASSIUM GLYCYRRHIZATE • CAPRYLIC/CAPRIC TRIGLYCERIDE • CAPRYLOYL SALICYLIC ACID • CAPRYLYL GLYCOL • CITRIC ACID • TRISODIUM ETHYLENEDIAMINE DISUCCINATE • XANTHAN GUM • PENTYLENE GLYCOL • OCTYLDODECANOL • RETINYL PALMITATE • TOCOPHEROL • PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE • PHENOXYETHANOL • CI 17200 / RED 33 • PARFUM / FRAGRANCE (F.I.L. N70037312/1).